All In Biotech

NDA 022043 · Janssen Lp

Invega

Paliperidone · Oral

Last checked: Nov 20, 2026Latest source record: Apr 27, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Apr 27, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

186

60 Phase 3, 3 recruiting

FAERS reports

23,466

11,599 serious, 845 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 27, 2007 Original approval · Type 6 - New Indication (no longer used) ReviewLetterLabel
4 products under this application
  • INVEGA · PALIPERIDONE 12MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • INVEGA · PALIPERIDONE 6MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • INVEGA · PALIPERIDONE 9MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • INVEGA · PALIPERIDONE 3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Paliperidone" as an intervention, any sponsor and status, largest first.

All 186 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injury4,330
  • gynaecomastia3,666
  • drug ineffective1,795
  • abnormal weight gain1,662
  • off label use1,565
  • weight increased1,390
  • hyperprolactinaemia1,272
  • galactorrhoea1,060
  • sedation762
  • dyskinesia717
  • dystonia715
  • treatment noncompliance684

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2007696
2008743
2009650
2010524
2011687
2012783
2013652
2014966
20152,359
20164,208
20173,453
2018910
2019847
2020814
2021812
2022932
2023924
2024801
20251,024
2026681

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Invega (Paliperidone)

2024 spending

$2.3M

Beneficiaries

704

4,179 claims

Per beneficiary

$3,336

$13.75 per unit

View as table
YearSpending
2020$122,657,282
2021$84,143,307
2022$25,750,207
2023$5,169,576
2024$2,348,551

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 332 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.